Candel Therapeutics (CADL) Operating Income: 2020-2023
Historic Operating Income for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to -$10.3 million.
- Candel Therapeutics' Operating Income fell 27.37% to -$10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$38.4 million, marking a year-over-year decrease of 10.57%. This contributed to the annual value of -$33.4 million for FY2024, which is 13.08% up from last year.
- Latest data reveals that Candel Therapeutics reported Operating Income of -$10.3 million as of Q4 2023, which was down 16.44% from -$8.9 million recorded in Q3 2023.
- Candel Therapeutics' Operating Income's 5-year high stood at -$2.3 million during Q2 2020, with a 5-year trough of -$10.3 million in Q4 2023.
- Over the past 3 years, Candel Therapeutics' median Operating Income value was -$8.8 million (recorded in 2022), while the average stood at -$8.2 million.
- As far as peak fluctuations go, Candel Therapeutics' Operating Income crashed by 192.07% in 2021, and later climbed by 0.23% in 2023.
- Candel Therapeutics' Operating Income (Quarterly) stood at -$6.1 million in 2020, then declined by 26.37% to -$7.7 million in 2021, then decreased by 4.66% to -$8.1 million in 2022, then declined by 27.37% to -$10.3 million in 2023.
- Its Operating Income was -$10.3 million in Q4 2023, compared to -$8.9 million in Q3 2023 and -$9.6 million in Q2 2023.